Edgewise Therapeutics, Inc. (EWTX) Stock

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. (EWTX) stock trades at $39.31 with a market capitalization of $4.23B. The stock is valued at a negative price-to-earnings (P/E) ratio of -21.95, reflecting a net loss over the last twelve months, price-to-book of 9.76, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $14.25 and $48.51, and currently trades 19.0% below its 52-week high.

On profitability, Edgewise Therapeutics, Inc. generates a return on equity (ROE) of -39.01% (negative, reflecting a net loss), return on capital employed of -48.57%.

Edgewise Therapeutics, Inc. by the numbers, 2019–2025

Between 2019 and 2025 Edgewise Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-168.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-197.0M.

Borrowings stand at $4.0M, cash from operations was $-144.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -25.6% over five years, and was -32.2% in the most recent year.

The share price itself has compounded at 6.2% a year over five years, 54.2% over three, 129.5% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Edgewise Therapeutics, Inc. (EWTX) — frequently asked questions